More On The Rimonabant Serenade Trial
"The trial achieved not only significant reduction in blood sugar levels but also in patient body weight - 6.7 kg compared to 2.7 kg in the placebo group. Results also showed improvements in (good) HDL cholesterol and triglicerides. This is unlike many currently approved diabetes treatments, where weight gain is a common and unwelcome side effect.
"This study suggests that rimonabant can achieve improvement in blood glucose with the added benefit of significant weight loss and improvement in other risk factors" said trial investigator Julio Rosenstock, MD, Director of the Dallas Diabetes and Endocrine Center at Medical City and Clinical Professor of Medicine at the University of Texas Southwestern Medical School, Dallas.
Nearly 300 patients throughout the US and six other countries took part in the SERENADE trial. The drug rimonabant is not currently available in the US although it has been approved in Europe."
acomplia
rimonabant
accomplia
0 Comments:
Post a Comment
<< Home